Eli Lilly Fell Like a Rock Over the Last Month: This Big Bank Expects 45% Returns Over The Next Twelve
Eli Lilly (LLY) closed at $1,114.90, with a consensus 12-month price target of $1,318.66 and Citi's target at $1,600. LLY dropped 8.44% in a month due to pricing concerns and IPR&D charges, despite Q2 revenue growth of 48% and raised 2026 guidance. Citi sees 45% upside, citing strong market share and pipeline prospects. Analysts remain mostly bullish, with 6 Strong Buy, 18 Buy, and 4 Hold ratings.
How this was made
The 30-second read
Why it matters
Guidance raise may trigger buying interest, but margin concerns could temper rally.
Market read
Lilly's guidance lift is a key catalyst for the biotech/healthcare sector and may influence peer valuations.
What to watch
Large IPR&D charges and potential margin squeeze from a 9% price decline may limit upside.
Background
Eli Lilly's stock has fallen 8.4% over the past month despite strong Q2 results; analysts are revising targets upward.
Ticker impact
Eli Lilly raised its full-year 2026 revenue guidance to $85‑87 billion and reported 48% YoY Q2 revenue growth, a fresh update not previously disclosed.
Potential upside of 15‑20% if market digests the guidance lift.
Guidance raise is a primary, material disclosure for a mega‑cap pharma; analysts already boosting targets, indicating bullish sentiment.
Market effects
Strengthens outlook for the GLP‑1 obesity/diabetes sector, may pressure peers lower.
U.S. pharma stocks could see modest gains as Lilly leads the rally.
Reinforces global weight‑loss drug demand narrative, affecting international peers.
Counterpoint
Price‑war pressure on GLP‑1 margins could erode earnings if discounting intensifies.
Key entities
- companyEli Lilly
US‑listed pharma leader in GLP‑1 drugs.
